Novartis AG NVS
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on NVS
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on NVS.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
NVS at a glance
NVS is priced at $162.55 right now, up 0.38% on the session. That puts its market value at $307.00B, 46th largest among the 3753 stocks we cover.
The stock's 52-week band runs $119.62 to $165.96, and the latest print sits 2.1% under the top end of it. Holders are ahead 32.5% over twelve months, and up 3.7% across the last three months.
On the chart it holds above both the 50-day ($148.83) and 200-day ($151.51) moving averages; RSI is 65, and the last 30 sessions moved at roughly 26% annualized volatility.
For the quarter ended Sep 2026 it reported $15.03B in revenue, up 4.7% from a year earlier, with $1.20B of net profit (a 17.5% margin).
Buyers are paying 31.0 times trailing earnings, 73% above its five-year average of 18.0. The median for its industry group is 42.0.
3 analysts follow the stock and the average call is "buy". The mean target, $171.50, sits 5.5% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 4 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
3 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
NVS is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.8% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $171.50, 5.5% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $130.00, so shares trade 25.0% above that estimate. On earnings multiple, it sits in the 97th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Novartis AG: the business
Novartis is a Swiss drugmaker focused on innovative medicines after spinning off Sandoz, with heart, immunology, cancer and neuroscience franchises.
What tends to move it. Sales of Entresto, which is losing patent protection, against newer drugs like Kisqali and Pluvicto, are the central question.
Where the case gets weaker. Entresto's patent cliff removes a major revenue source on a known timeline, and if Kisqali and Pluvicto don't grow fast enough to offset that decline, overall sales growth would stall until the next wave of pipeline products arrives.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +4.9% | Bullish |
| Price vs 50-day average | +9.2% | Bullish |
| Price vs 200-day average | +7.3% | Bullish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 64.5 | Bullish |
| MACD (12,26,9) | 4.33 | Bullish |
| Bollinger band position | 80% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 6, 2026 8:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
How NVS ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 31.0x earnings, NVS looks expensive against the market, and trades 26% below the 42.0x median among CAR-T Therapy names. The two comparisons do not always agree.
NVS stock: common questions
How is Novartis AG stock doing today?
$162.55 is the latest print for NVS, a move of +0.38% against yesterday's close of $161.93. Today's low and high so far: $159.36 and $163.11.
What is NVS worth in total?
Equity value comes to $307.00B at the current price. By that measure it is number 46 of the 3753 names in our coverage.
How is Novartis AG valued against its profits?
Buyers pay 31.0 times the last twelve months of profit (EPS $7.15). Averaged over five years the multiple has been 18.0, and today's level ranks in the 97th percentile of its own history.
Is NVS near its 52-week high or low?
The year's floor is $119.62 and the ceiling $165.96. Shares are 2.1% away from that ceiling.
Does Novartis AG pay a dividend?
It does. Payouts over the past twelve months work out to a 2.92% yield; the latest ex-dividend date was March 11, 2026.
Is NVS rated a buy by Wall Street?
Of 3 analysts, 67% say buy, 33% hold and 0% sell. Price targets average $171.50, with the most cautious at $163.00 and the most optimistic at $180.00.
What kind of company is Novartis AG?
Novartis is a Swiss drugmaker focused on innovative medicines after spinning off Sandoz, with heart, immunology, cancer and neuroscience franchises.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on NVS.
Sign in to join the discussion.